NRx Pharma: Positive Safety Report for NIH Sponsored Study in Life-Threatening COVID-19

 After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 600 Patients

- ACTIV-3 Critical Care is a Public-Private Partnership Sponsored by the US National Institutes of Health to Treat COVID-19

- ACTIV-3 Critical Care is Evaluating ZYESAMI™ and Remdesivir, in Critical COVID-19 Patients, as Monotherapy and in Combination Against Placebo

https://finance.yahoo.com/news/nrx-pharmaceuticals-announces-positive-safety-155300349.html